132 related articles for article (PubMed ID: 9436457)
1. [Molecular biology and immunology of acetylcholine receptor in relation to myasthenia gravis].
Takamori M; Komai K; Iwasa K; Yoshikawa H
Nihon Rinsho; 1997 Dec; 55(12):3315-21. PubMed ID: 9436457
[TBL] [Abstract][Full Text] [Related]
2. Ryanodine receptor autoantibodies in myasthenia gravis patients with a thymoma.
Mygland A; Tysnes OB; Matre R; Volpe P; Aarli JA; Gilhus NE
Ann Neurol; 1992 Oct; 32(4):589-91. PubMed ID: 1333745
[TBL] [Abstract][Full Text] [Related]
3. On the initial trigger of myasthenia gravis and suppression of the disease by antibodies against the MHC peptide region involved in the presentation of a pathogenic T-cell epitope.
Atassi MZ; Oshima M; Deitiker P
Crit Rev Immunol; 2001; 21(1-3):1-27. PubMed ID: 11642597
[TBL] [Abstract][Full Text] [Related]
4. Specificity of the T cell immune response to acetylcholine receptor in experimental autoimmune myasthenia gravis. Response to subunits and synthetic peptides.
Fujii Y; Lindstrom J
J Immunol; 1988 Mar; 140(6):1830-7. PubMed ID: 2450133
[TBL] [Abstract][Full Text] [Related]
5. [Biochemical approaches to neuromuscular junction disorders].
Takamori M
Rinsho Shinkeigaku; 1996 Dec; 36(12):1363-4. PubMed ID: 9128412
[TBL] [Abstract][Full Text] [Related]
6. [A joint undertaking by molecular biology and immunology in search for the pathogenesis of neuromuscular synaptic disorders].
Takamori M
Nihon Rinsho; 1997 Dec; 55(12):3106-13. PubMed ID: 9436419
[TBL] [Abstract][Full Text] [Related]
7. [Myasthenia gravis: pathogenesis and therapeutic approach on the basis of molecular structure and immunogenicity of acetylcholine receptor].
Takamori M
Nihon Rinsho; 1994 Nov; 52(11):3038-45. PubMed ID: 7996707
[TBL] [Abstract][Full Text] [Related]
8. Spontaneous thymoma rat as a model for myasthenic weakness caused by anti-ryanodine receptor antibodies.
Iwasa K; Komai K; Takamori M
Muscle Nerve; 1998 Dec; 21(12):1655-60. PubMed ID: 9843065
[TBL] [Abstract][Full Text] [Related]
9. [Antibodies in myasthenia gravis].
Eymard B
Rev Neurol (Paris); 2009 Feb; 165(2):137-43. PubMed ID: 19162288
[TBL] [Abstract][Full Text] [Related]
10. A pathogenetic role for the thymoma in myasthenia gravis. Autosensitization of IL-4- producing T cell clones recognizing extracellular acetylcholine receptor epitopes presented by minority class II isotypes.
Nagvekar N; Moody AM; Moss P; Roxanis I; Curnow J; Beeson D; Pantic N; Newsom-Davis J; Vincent A; Willcox N
J Clin Invest; 1998 May; 101(10):2268-77. PubMed ID: 9593783
[TBL] [Abstract][Full Text] [Related]
11. A 17-Mer self-peptide of acetylcholine receptor binds to B cell MHC class II, activates helper T cells, and stimulates autoantibody production and electrophysiologic signs of myasthenia gravis.
Yoshikawa H; Lambert EH; Walser-Kuntz DR; Yasukawa Y; McCormick DJ; Lennon VA
J Immunol; 1997 Aug; 159(3):1570-7. PubMed ID: 9233656
[TBL] [Abstract][Full Text] [Related]
12. Autoimmunity against the ryanodine receptor in myasthenia gravis.
Skeie GO; Lunde PK; Sejersted OM; Mygland A; Aarli JA; Gilhus NE
Acta Physiol Scand; 2001 Mar; 171(3):379-84. PubMed ID: 11412151
[TBL] [Abstract][Full Text] [Related]
13. Striational antibodies in myasthenia gravis: reactivity and possible clinical significance.
Romi F; Skeie GO; Gilhus NE; Aarli JA
Arch Neurol; 2005 Mar; 62(3):442-6. PubMed ID: 15767509
[TBL] [Abstract][Full Text] [Related]
14. Enzyme-linked immunosorbent assay for antibody against the nicotinic acetylcholine receptor in human myasthenia gravis.
Kawanami S; Tsuji R; Oda K
Ann Neurol; 1984 Feb; 15(2):195-200. PubMed ID: 6367620
[TBL] [Abstract][Full Text] [Related]
15. In vitro proliferative responses and antibody titers specific to human acetylcholine receptor synthetic peptides in patients with myasthenia gravis and relation to HLA class II genes.
Brocke S; Brautbar C; Steinman L; Abramsky O; Rothbard J; Neumann D; Fuchs S; Mozes E
J Clin Invest; 1988 Dec; 82(6):1894-900. PubMed ID: 2461962
[TBL] [Abstract][Full Text] [Related]
16. The severity of myasthenia gravis correlates with the serum concentration of titin and ryanodine receptor antibodies.
Romi F; Skeie GO; Aarli JA; Gilhus NE
Arch Neurol; 2000 Nov; 57(11):1596-600. PubMed ID: 11074791
[TBL] [Abstract][Full Text] [Related]
17. Ryanodine receptor antibodies in myasthenia gravis: epitope mapping and effect on calcium release in vitro.
Skeie GO; Mygland A; Treves S; Gilhus NE; Aarli JA; Zorzato F
Muscle Nerve; 2003 Jan; 27(1):81-9. PubMed ID: 12508299
[TBL] [Abstract][Full Text] [Related]
18. Role of the main immunogenic region of acetylcholine receptor in myasthenia gravis. An Fab monoclonal antibody protects against antigenic modulation by human sera.
Tzartos SJ; Sophianos D; Efthimiadis A
J Immunol; 1985 Apr; 134(4):2343-9. PubMed ID: 3973387
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of experimental autoimmune myasthenia gravis by major histocompatibility complex class II competitor peptides results not only in a suppressed but also in an altered immune response.
Wauben MH; Hoedemaekers AC; Graus YM; Wagenaar JP; van Eden W; de Baets MH
Eur J Immunol; 1996 Dec; 26(12):2866-75. PubMed ID: 8977279
[TBL] [Abstract][Full Text] [Related]
20. Anti-ryanodine receptor-positive acetylcholine receptor-negative myasthenia gravis: evidence of impaired excitation-contraction coupling.
Imai T; Tsuda E; Toyoshima T; Yoshikawa H; Motomura M; Shimohama S
Muscle Nerve; 2011 Feb; 43(2):294-5. PubMed ID: 21254099
[No Abstract] [Full Text] [Related]
[Next] [New Search]
